



George Clinical is the Global Kidney CRO

Science. Service. Solutions.

Founded in Asia-Pacific and driven by scientific expertise and operational excellence, George Clinical is a leading, global clinical research organization with over 20 years of experience. We proudly employ over 500 experienced people in 40 locations who can manage clinical trials in up to 70 geographies throughout the Asia-Pacific region, North America and Europe. George Clinical provides the full range of clinical trial services to biotech, pharmaceutical, medical device and diagnostic customers, for all phases, registration and post-marketing trials.

At a Glance



Global network of distinguished scientific leaders with expertise in chronic disease.



Leading Asia-Pacific full service CRO with global capabilities tested over more than 20 years.



Driver of the Global Kidney Patients Trials Network (GKPTN) which accelerates kidney research into practice.



Access to the Clinical Research Network (CRN) infrastructure supporting clinical research in the UK and European Union.

Scientific Expertise

Facilitated by a kidney site network considered to be one of the strongest in the world, especially in the Asia Pacific region, George Clinical owns an enviable position as a trusted partner in kidney and metabolic clinical research around the globe. Our scientific expertise collaborates with sponsors to develop new strategies for the prevention and management of kidney and metabolic disease specifically including dialysis, chronic kidney disease (CKD), focal segmental glomerulosclerosis (FSGS), diabetic kidney disease, acute kidney injury and IgA nephropathy as well as the utility of genetics in drug development and discovery.

George Clinical leverages the in-depth expertise of our scientific leadership to design effective studies, select the best sites from more than 20 countries, and accelerate recruitment. Our scientific leaders generate strong evidence to implement real change in treatments, clinical practice and policy.

Kidney & Metabolic Trials

George Clinical's experienced researchers have a track record of developing new strategies for the prevention of kidney disease by targeting their primary risk factors such as high blood pressure and diabetes. George Clinical leverages this in-depth knowledge and prominence in the kidney and metabolic field to facilitate effective studies.

Clinical Trial Services

- Scientific Services: Medical Writing, Endpoint Adjudication, Program and Protocol Design, Scientific Leadership and Data Safety Management Board (DSMB)
- Project & Site Management: Project Management, Site Management, Trial Delivery and Risk-Based Monitoring
- Data Services
- Regulatory Services
- Health Economics
- Real-World Evidence Research
- Safety and Pharmacovigilance Services

Some of George Clinical's success in kidney and metabolic studies include:

TESTING

The largest IgA nephropathy RCT in the world to date randomized 503 patients and provided critical data and guidance on the net benefit or harm of corticosteroid therapy in IgA nephropathy with results leading the way for future trials to assess the development of safer treatment regimens.

Oral Treatment Study

Provided global scientific leadership and oversight including 51 National Leaders in a multi-trial, multi-year study of a potential new oral treatment for both dialysis and non-dialysis patients with CKD associated anemia, enrolling more than 8,000 patients in 41 countries and lasting more than four years.

IGA Studies

Recently involved in multiple IgA nephropathy trials across more than 50 countries in APAC, EMEA and North and South America involving more than 3,000 patients in studies testing new drugs to potentially give more targeted and less toxic treatment options.

Rare Diseases Studies Overview

Involved in rare kidney disease studies and innovative trial designs including basket and adaptive approaches providing a platform for assessing multiple interventions to help increase numbers of trials and speed development of tailored effective therapies for small subgroups such as FSGS, membranous nephropathy or C3G patients.

Multi-Country Trials

A number of multi-country trials with global pharmaceutical companies investigating renal outcomes in diabetic kidney disease. This includes an evaluation of a new chemical entity with project management and monitoring across 137 sites and seven countries.

CKD Non-Diabetic Studies

Providing scientific leadership as well as operations in multiple global CKD studies across APAC, EMEA and the Americas addressing aspects such as fluid and metabolic imbalances and anemia for both diabetic and non-diabetic patients and supporting the development of novel therapies to slow or prevent end stage kidney disease.



Leading the Way in Kidney Research

Global Kidney Patients Trials Network (GKPTN)

Accelerating kidney research and improving the quality of care for patients with kidney disease requires innovative thinking and challenging the status quo. Our team of world-class scientific leaders and operational experts connect key opinion leaders, investigators, research sites, patients, regulators and clients with a common purpose and an innovative operational platform for conducting kidney clinical trials. The GKPTN is endorsed by the International Society of Nephrology and aims to work with kidney disease networks globally. Collaboratively, we will take kidney research to the next level across the globe. By bringing patients, established sites and trials closer together, GKPTN aims to strengthen the global kidney disease research community's capacity to facilitate more rapid translation of new interventions from research into practice.

How can we accelerate treatments to patients with kidney disease?

Kidney disease stands prominently as a global health problem due to its increasing prevalence and costly burden placed on individual patients and the entire healthcare system. Novel treatments to reduce the risk of kidney and cardiovascular complications represent the best solution. This path requires innovative approaches, such as structures that facilitate rapid access to trials for interested patients, trial designs that enable efficient testing of multiple agents and stable infrastructures that facilitate continued research activity by regional health services. Each piece of this equation benefits from the network effect of a global platform that accelerates the discovery of novel treatments for patients with chronic kidney disease.

What does the GKPTN help accomplish?

- Allows for the ongoing and long-term collection of critical data from patients suffering from kidney disease that will be analyzed for future treatment pathways and important interventions
- Establishes global infrastructure in a collaborative fashion to facilitate rapid and improved access to trials for patients with kidney disease
- Improves patient outcomes by hosting embedded trials with novel designs to efficiently test multiple agents faster and more efficiently than current approaches
- Reduces study costs through a central protocol, efficient and rapid recruitment, and proven operational synergies
- Shortens timelines to key decision milestones and commercialization so that innovative treatments get to patients faster
- Globally hosts kidney disease patients both inside and outside of current clinical trials for a comprehensive evaluation of kidney disease
- Provides confirmed feasibility with pre-approved sites

Meet our world-class scientific leadership team with extensive knowledge and experience in kidney and metabolic trials.



Research Methodology


Kidney trial specialists collaborating across the globe empower the platform to improve patient outcomes by facilitating internal evaluation of numerous kidney diseases and allowing access in some cases to trial operations that generate evidence about the efficacy and safety of new treatment strategies. Networked project teams in the platform recruit patients with chronic kidney disease interested in participating in clinical research and then provide them rapid access to relevant clinical trials as they become available. Participants consent to be approached about participation in current or future trials, as well as agree to follow up visits every six months for a minimum of five years along with bio-banking of blood samples at time of recruitment.

Hosted trials recruit “trial-ready” patients from sources within the platform, governed in a centralized collaborative manner, and incorporate innovative trial methodology and pragmatic operational practices. By bringing patients, established sites and trials closer together, GKPTN aims to strengthen the global kidney disease research community’s capacity to facilitate more rapid translation of new interventions from research into practice.



Global Reach

George Clinical has grown rapidly and continues to develop and enhance operations around the globe. Headquartered in Sydney, Australia, George Clinical is located across Asia Pacific (Australia, New Zealand, China, Hong Kong, Taiwan, South Korea, Malaysia, Singapore, Philippines and India), Europe (UK, the Netherlands, Spain, Italy and Latvia) and the United States of America. We also provide services in Japan, Indonesia, Sri Lanka, Thailand, Central Eastern Europe and Latin America.



Contact us to explore how we can leverage our scientific leadership, responsive service and results-focused clinical research solutions for your organization today.



info@georgeclinical.com
georgeclinical.com
georgeclinical.cn